Electrodiagnostic Testing (EMG/NCV) - (CPG129) | CIGNA Coverage Update

Cigna modified CPG129 (cpg129_emg_ncv_ssep) covering electrodiagnostic testing — EMG, NCV, and SSEP studies — effective October 16, 2025. Here's what billing teams need to do.

Cigna Healthcare updated its clinical policy guideline CPG129 for electrodiagnostic testing, aligning coverage criteria with the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) recommendations. The update affects 29 CPT codes — including 95860–95913 for needle EMG and nerve conduction studies, and 95925–95938 for somatosensory evoked potentials — plus one HCPCS code (S3900 for surface EMG). If your practice bills EMG/NCV studies for neurology, physical medicine, or pain management patients under Cigna plans, audit your charge capture and documentation before October 16, 2025.

Quick-Reference Table

Cigna Electrodiagnostic Testing Coverage Criteria and Medical Necessity Requirements 2025

The Cigna electrodiagnostic testing coverage policy under cpg129_emg_ncv_ssep Cigna system now formally adopts AANEM standards as the baseline for medical necessity determinations. This is the central change. Cigna isn't inventing new criteria — it's deferring to AANEM's published guidance on when nerve conduction studies, needle electromyography, and somatosensory evoked potentials (SEPs) are clinically appropriate.

What that means in practice: your documentation needs to map to AANEM-endorsed indications. If your physicians are ordering EMG studies without documenting the clinical question being answered — suspected radiculopathy, peripheral neuropathy, neuromuscular junction disorder — expect Cigna to push back.

The cpg129 Cigna policy covers needle EMG (CPT 95860–95870, 95885–95887) and nerve conduction studies (CPT 95907–95913) when AANEM criteria are met. Neuromuscular junction testing (CPT 95937) and somatosensory evoked potentials (CPT 95925, 95926, 95927, 95938) also require documented clinical necessity under the same AANEM framework.

The breadth of covered ICD-10 diagnoses is substantial — 1,459 codes in total. That list includes diabetic neuropathy (E08.40–E08.49, E09.40–E09.49), postherpetic neuropathy (B02.23), Lyme disease (A69.20), HIV (B20), botulism (A05.1, A48.52), leprosy (A30.x), poliomyelitis sequelae (B91), and malignant spinal cord neoplasms (C72.0, C72.1). Coverage is broad, but it is diagnosis-driven. Bill with specificity.

The Cigna EMG/NCV coverage policy does not outline a blanket prior authorization requirement within CPG129 itself. However, prior authorization requirements vary by plan. Check the member's specific plan benefits before scheduling electrodiagnostic testing. If you're billing a high volume of 95913 (13 or more nerve conduction studies), that's exactly the kind of claim pattern that triggers utilization review — and you want your documentation ironclad before that review happens.

Cigna Electrodiagnostic Testing Exclusions and Non-Covered Indications

Two codes get clear negative coverage designations under this policy. Know them cold.

CPT 95905 — Motor and/or sensory nerve conduction using preconfigured electrode arrays — is considered not medically necessary. The policy flags this as automated testing. Cigna's position is that automated, preconfigured array testing doesn't meet the clinical standard for nerve conduction studies. If your practice uses automated NCV devices and bills 95905, those claims are headed for denial.

HCPCS S3900 — Surface EMG — is classified as experimental/investigational and unproven. Surface EMG has a long history of coverage battles across payers. Cigna's position here is consistent with what you've seen from other major payers. If you're billing S3900 under any Cigna plan, stop. Reimbursement for this code under Cigna is not available under this coverage policy, and that's unlikely to change without a major shift in clinical evidence.

Coverage Indications at a Glance

Cigna EMG/NCV Billing Guidelines and Action Items 2025

The effective date is October 16, 2025. That's your deadline. Here's what to do before it arrives.

1. Audit your documentation templates against AANEM criteria.
Cigna's medical necessity standard is now explicitly AANEM-based. Pull your current EMG/NCV order and documentation templates. Compare them against AANEM's published guidelines for nerve conduction studies and needle electromyography. Every order should capture the clinical question being asked, the suspected diagnosis, and why electrodiagnostic testing is the appropriate next step.

2. Remove CPT 95905 from your Cigna charge capture.
If your practice uses automated nerve conduction devices and has been billing 95905 under Cigna, stop before October 16, 2025. This code is not medically necessary under this coverage policy. Continuing to bill it generates claim denials and potential overpayment liability. If you're not sure which device your techs are using, ask — and get it in writing.

3. Flag HCPCS S3900 as non-billable to Cigna.
Update your charge master and billing guidelines to block S3900 from generating Cigna claims. Surface EMG billing under Cigna has no path to reimbursement under cpg129_emg_ncv_ssep. This isn't a gray area.

4. Justify the number of nerve conduction studies you're performing.
CPT 95907 through 95913 scale by the number of studies performed — one to two studies up through 13 or more. High-study-count claims (95912, 95913) are a utilization review target. Document why each study in the series was clinically necessary. "Rule out peripheral neuropathy" isn't enough — document what clinical findings drove the decision to expand the study.

5. Verify plan-level prior authorization requirements separately.
CPG129 doesn't mandate prior authorization universally, but individual Cigna plan contracts may. Before October 16, 2025, verify your auth requirements by plan type — commercial, Medicare Advantage, and Cigna supplemental plans may differ. A missed prior auth is a clean claim denial with no clinical ambiguity to argue — just a process failure.

6. Check your diagnosis coding specificity.
With 1,459 covered ICD-10-CM codes in scope, the diagnosis list is expansive. But broad coverage doesn't mean vague coding. Use the most specific ICD-10-CM code available. If your patient has diabetic polyneuropathy, bill E11.42 (or the appropriate diabetes type equivalent from the E08–E13 range), not a general neuropathy code. Specificity supports medical necessity and reduces audit exposure.

7. Talk to your compliance officer if you bill high volumes of 95913.
Billing 13 or more nerve conduction studies per encounter (CPT 95913) is not inherently wrong — complex cases warrant it. But it's a pattern Cigna's utilization management team watches. If your practice regularly bills at this level, loop in your compliance officer to confirm your documentation practices hold up under retrospective review.

CPT, HCPCS, and ICD-10 Codes for Electrodiagnostic Testing Under cpg129_emg_ncv_ssep

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Not Covered / Experimental Codes

Key ICD-10-CM Diagnosis Codes (Representative Sample — 1,459 Total in Policy)

The full ICD-10-CM list in the policy contains 1,459 diagnosis codes. Review the complete code set at the Cigna CPG129 source policy before updating your billing guidelines.